Xeris Biopharma Holdings, Inc. (FRA:2B30)

Xeris Biopharma Holdings Statistics

Total Valuation

FRA:2B30 has a market cap or net worth of EUR 993.39 million. The enterprise value is 1.14 billion.

Market Cap	993.39M
Enterprise Value	1.14B

Important Dates

The next estimated earnings date is Monday, March 9, 2026.

Earnings Date	Mar 9, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	165.92M
Shares Outstanding	n/a
Shares Change (YoY)	+8.48%
Shares Change (QoQ)	+11.39%
Owned by Insiders (%)	4.42%
Owned by Institutions (%)	59.20%
Float	158.60M

Valuation Ratios

PE Ratio	n/a
Forward PE	24.01
PS Ratio	4.38
PB Ratio	-1,353.70
P/TBV Ratio	n/a
P/FCF Ratio	116.85
P/OCF Ratio	110.39
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 35.38, with an EV/FCF ratio of 133.65.

EV / Earnings	-85.24
EV / Sales	4.96
EV / EBITDA	35.38
EV / EBIT	83.06
EV / FCF	133.65

Financial Position

The company has a current ratio of 1.93

Current Ratio	1.93
Quick Ratio	1.25
Debt / Equity	n/a
Debt / EBITDA	6.90
Debt / FCF	25.83
Interest Coverage	0.54

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	2.88%
Return on Invested Capital (ROIC)	3.98%
Return on Capital Employed (ROCE)	6.26%
Revenue Per Employee	575,707
Profits Per Employee	-33,832
Employee Count	394
Asset Turnover	0.77
Inventory Turnover	0.73

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +104.93% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+104.93%
50-Day Moving Average	6.99
200-Day Moving Average	5.20
Relative Strength Index (RSI)	39.43
Average Volume (20 Days)	227

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.67

Income Statement

In the last 12 months, FRA:2B30 had revenue of EUR 226.83 million and -13.33 million in losses. Loss per share was -0.09.

Revenue	226.83M
Gross Profit	191.80M
Operating Income	13.55M
Pretax Income	-13.33M
Net Income	-13.33M
EBITDA	23.90M
EBIT	13.55M
Loss Per Share	-0.09

Balance Sheet

The company has 78.07 million in cash and 219.60 million in debt, giving a net cash position of -141.53 million.

Cash & Cash Equivalents	78.07M
Total Debt	219.60M
Net Cash	-141.53M
Net Cash Per Share	n/a
Equity (Book Value)	-733,830
Book Value Per Share	-0.00
Working Capital	91.89M

Cash Flow

In the last 12 months, operating cash flow was 9.00 million and capital expenditures -496,891, giving a free cash flow of 8.50 million.

Operating Cash Flow	9.00M
Capital Expenditures	-496,891
Free Cash Flow	8.50M
FCF Per Share	n/a

Margins

Gross margin is 84.56%, with operating and profit margins of 5.98% and -5.88%.

Gross Margin	84.56%
Operating Margin	5.98%
Pretax Margin	-5.88%
Profit Margin	-5.88%
EBITDA Margin	10.53%
EBIT Margin	5.98%
FCF Margin	3.75%

Dividends & Yields

FRA:2B30 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.48%
Shareholder Yield	-8.48%
Earnings Yield	-1.34%
FCF Yield	0.86%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:2B30 has an Altman Z-Score of -0.2 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.2
Piotroski F-Score	6